Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

40 results about "Neospora species" patented technology

Neospora caninum is a coccidian parasite that was identified as a species in 1988. Prior to this, it was misclassified as Toxoplasma gondii due to structural similarities. The genome sequence of Neospora caninum has been determined by the Wellcome Trust Sanger Institute and the University of Liverpool.

Neosporosis recombinant enzyme-linked immunosorbent assay (rELISA) antibody assay kit

The invention provides a neosporosis rELISA antibody assay kit. The neosporosis recombinant enzyme-linked immunosorbent assay (rELISA) antibody assay kit is characterized in that designing a primer set according to a neospora caninum NcSRS2 gene of the GenBank, introducing the primer set to an enzyme digestion site, removing a signal peptide zone of an NcSRS2 protein, extracting a DNA from Xinjiang cow positive serum, carrying out polymerase chain reaction (PCR) amplification of the DNA to obtain a tNcSRS2 genetic fragment having length of 975bp, cloning the tNcSRS2 genetic fragment into a pMD-18-T carrier, carrying out enzyme digestion and sequencing, further directionally connecting the desired fragment obtained by the previous step to a pGEX-4T-2 expression carrier, transferring the pGEX-4T-2 expression carrier with the desired fragment into escherichia coli, carrying out inducible expression and purification, wherein expressed fusion protein molecular weight is about 62kDa, and carrying out ELISA antigen coating by the expressed fusion protein to obtain the neosporosis rELISA antibody assay kit. A use method of the neosporosis rELISA antibody assay kit comprises the following steps that a coated enzyme label reaction plate is taken out, is subjected to first washing, is enclosed, is subjected to second washing, is added with a sample needing to be detected, is subjected to third washing, is added with a secondary antibody, is subjected to fourth washing, and undergoes a color reaction; and when the color reaction is finished, an OD450/630 value of the coated enzyme label reaction plate is read and a result is determined. Compared with a commercial ELISA assay kit, the neosporosis rELISA antibody assay kit has a higher coincidence rate above 95% The neosporosis rELISA antibody assay kit also is suitable for the ELISA of a neospora caninum antibody in ruminant serum and blood plasma.
Owner:XINJIANG AGRI UNIV

Novel Neospora caninum Vaccine

InactiveUS20090208519A1Reduce severityPrevent and to decrease severityProtozoa antigen ingredientsViral antigen ingredientsBALB/cBuprestis novemmaculata
Neospora caninum is the causal agent of bovine neosporosis which results in high levels of abortion. The present study determined the protective efficacy of two Neospora antigens—Neospora cyclophilin (NcCyP) and NcSRS2. The ability of native NcCyP to upregulate mouse IFNγ was also confirmed in this study. Recombinant NcCyP or NcSRS2 were tested either alone or in combination and formulated with adjuvant ImmuMax-SR and CpG. Female BALB/c mice (n=15) of 10-12 weeks of age were immunized s.c. twice in a 2-week interval with vaccines containing either NcCyP alone, NcSRS2 alone, NcCyP plus NcSRS2, or non-recombinant bacterial antigen (NR) in 2 separate trials. All mice were challenge-infected 3 weeks following the booster immunization and necropsied 3 weeks after the challenge infection. Brain and serum were collected and Nc-specific DNA sequence in brain tissue and antibodies in serum were analyzed by PCR or ELISA/Western blotting. Results showed that mice vaccinated with rNcCyP, rNcSRS2, or both rNcCyP and rNcSRS2 responded with high levels of NcCyP or NcSRS2 specific antibodies. Overall, mice received vaccines formulated with either rNcCyP or rNcCyP and rNcSRS2 had a higher (p<0.01) percent protection when compared to the mock- or non-vaccinated mice. The groups immunized with rNcSRS2 alone exhibited slightly lower levels of protection, which was higher (p<0.05) than that of the non-vaccinated group but did not differ (p=0.06) from that of the mock-vaccinated group. The results of the present study indicate that NcCyP is a highly efficacious vaccine candidate which may be useful in protection against Neospora infection.
Owner:UNITED STATES OF AMERICA

Applications of rabbit encephalitozoon cuniculi spore wall protein SWP1 to preparation of reagent for diagnosing or detecting rabbit encephalitozoon cuniculi infection

InactiveCN103728458AIncreased sensitivityBiological testingFermentationCryptosporidium infectionSparganosis
The invention discloses application of rabbit encephalitozoon cuniculi spore wall protein SWP1 to preparation of a reagent for diagnosing or detecting rabbit encephalitozoon cuniculi infection. A specific primer is designed according to the gene sequence of the rabbit encephalitozoon cuniculi spore wall protein SWP1, published by a database of NCBI (National Center of Biotechnology Information), and is amplified in a fox kidney sample infected with encephalitozoon cuniculi to obtain the SWP1nucleotide sequence shown as SEQ ID NO.2. The fused-expressed SWP1-GST is used for the detection of the sample, the result shows that the fused-expressed SWP1-GST protein has good specificity on the detection of fox serum infected with rabbit encephalitozoo cuniculi, and has no cross reaction with positive serum infected with toxoplasma gondii, neospora caninum and cryptosporidium. In addition, the research result shows that the sensitivity of the SWP1 protein, which is taken as a detection antigen, is obviously higher than that of the PTP2 (Protein-tyrosine-phosphatase 2) protein as a detection antigen. Therefore, the method for diagnosing or detecting the rabbit encephalitozoonosis cuniculi is high in sensitivity, and the diagnosis and prevention of the rabbit encephalitozoonosis cuniculi are further promoted.
Owner:HARBIN VETERINARY RES INST CHINESE ACADEMY OF AGRI SCI +3

Neosporosis recombinant enzyme-linked immunosorbent assay (rELISA) antibody assay kit

The invention provides a neosporosis rELISA antibody assay kit. The neosporosis recombinant enzyme-linked immunosorbent assay (rELISA) antibody assay kit is characterized in that designing a primer set according to a neospora caninum NcSRS2 gene of the GenBank, introducing the primer set to an enzyme digestion site, removing a signal peptide zone of an NcSRS2 protein, extracting a DNA from Xinjiang cow positive serum, carrying out polymerase chain reaction (PCR) amplification of the DNA to obtain a tNcSRS2 genetic fragment having length of 975bp, cloning the tNcSRS2 genetic fragment into a pMD-18-T carrier, carrying out enzyme digestion and sequencing, further directionally connecting the desired fragment obtained by the previous step to a pGEX-4T-2 expression carrier, transferring the pGEX-4T-2 expression carrier with the desired fragment into escherichia coli, carrying out inducible expression and purification, wherein expressed fusion protein molecular weight is about 62kDa, and carrying out ELISA antigen coating by the expressed fusion protein to obtain the neosporosis rELISA antibody assay kit. A use method of the neosporosis rELISA antibody assay kit comprises the following steps that a coated enzyme label reaction plate is taken out, is subjected to first washing, is enclosed, is subjected to second washing, is added with a sample needing to be detected, is subjected to third washing, is added with a secondary antibody, is subjected to fourth washing, and undergoes a color reaction; and when the color reaction is finished, an OD450 / 630 value of the coated enzyme label reaction plate is read and a result is determined. Compared with a commercial ELISA assay kit, the neosporosis rELISA antibody assay kit has a higher coincidence rate above 95% The neosporosis rELISA antibody assay kit also is suitable for the ELISA of a neospora caninum antibody in ruminant serum and blood plasma.
Owner:XINJIANG AGRI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products